Amgen’s burgeoning biosimilar presence continues to grow apace and now the company has eyes firmly on the US market for eculizumab after brokering a deal with originator Alexion. The biosimilars developer chose to settle on three of Alexion’s patents ahead of a trial later this year.

Mylan’s proposed $12bn combination with Pfizer’s Upjohn unit is expected to close next month following a settlement agreement with the FTC, with a requirement to address competition concerns in ten markets. The FTC was however strongly divided on the deal, with dissenters labelling the directives of the Commission as “deeply flawed, favoring routine over rigor.”

Almost 500 days after the transaction was first announced, Viatris, the proposed combination of Mylan and Pfizer’s Upjohn, is set to receive word from the US Federal Trade Commission, representing the last major obstacle to getting the deal over the line.